Evidence map›Paper›PMID 26355749›Full record

ArticlePloS one2015

Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidae during Evolution.

Eva M Schmidt, Constanze Wiek, Oliver T Parkinson, Katharina Roellecke, Marcel Freund, Michael Gombert, Nadine Lottmann, Charles A Steward, Christof M Kramm, Vladimir Yarov-Yarovoy and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol.The Journal of pharmacology and experimental therapeutics · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Eva M SchmidtDepartment of Pediatric Hematology, Oncology and Clinical Immunology, Children's Hospital, Heinrich Heine University, 40225 Düsseldorf, Germany.
Constanze WiekDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Oliver T ParkinsonDepartment of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98195, United States of America.
Katharina RoelleckeDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Marcel FreundDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Michael GombertDepartment of Pediatric Hematology, Oncology and Clinical Immunology, Children's Hospital, Heinrich Heine University, 40225 Düsseldorf, Germany.
Nadine LottmannDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Charles A StewardWellcome Trust Sanger Institute, Cambridge, United Kingdom.
Christof M KrammDivision of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University of Göttingen, 37099 Göttingen, Germany.
Vladimir Yarov-YarovoyDepartments of Physiology and Membrane Biology, University of California Davis, Davis, CA 95616, United States of America.
Allan E RettieDepartment of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98195, United States of America.
Helmut HanenbergDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, United States of America; Department of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.
Heinrich Heine University Düsseldorf · DEUniversity of Washington · USUniversity of California, Davis · USUniversity of Göttingen · DEWellcome Sanger Institute · GB

Funding

MECHANISMS OF P450 DEPENDENT DESATURATIONR01GM049054 · NIGMS · UNIVERSITY OF WASHINGTON · PI RETTIE, ALLAN EDWARD · 1994 to 2010
$2.9M
Genetic Therapy for Fanconi AnemiaR01CA155294 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI CLAPP, DAVID W, HANENBERG, HELMUT · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA155294NIGMS NIH HHS R01 GM049054NIGMS NIH HHS R01 GM49054
6 · The paper itself

Abstract

CYP4B1 belongs to the cytochrome P450 family 4, one of the oldest P450 families whose members have been highly conserved throughout evolution. The CYP4 monooxygenases typically oxidize fatty acids to both inactive and active lipid mediators, although the endogenous ligand(s) is largely unknown. During evolution, at the transition of great apes to humanoids, the CYP4B1 protein acquired a serine instead of a proline at the canonical position 427 in the meander region. Although this alteration impairs P450 function related to the processing of naturally occurring lung toxins, a study in transgenic mice suggested that an additional serine insertion at position 207 in human CYP4B1 can rescue the enzyme stability and activity. Here, we report that the genomic insertion of a CAG triplet at the intron 5-exon 6 boundary in human CYP4B1 introduced an additional splice acceptor site in frame. During evolution, this change occurred presumably at the stage of Hominoidae and leads to two major isoforms of the CYP4B1 enzymes of humans and great apes, either with or without a serine 207 insertion (insSer207). We further demonstrated that the CYP4B1 enzyme with insSer207 is the dominant isoform (76%) in humans. Importantly, this amino acid insertion did not affect the 4-ipomeanol metabolizing activities or stabilities of the native rabbit or human CYP4B1 enzymes, when introduced as transgenes in human primary cells and cell lines. In our 3D modeling, this functional neutrality of insSer207 is compatible with its predicted location on the exterior surface of CYP4B1 in a flexible side chain. Therefore, the Ser207 insertion does not rescue the P450 functional activity of human CYP4B1 that has been lost during evolution.

Indexed as

Biological EvolutionAdultAlternative SplicingAnimalsAryl Hydrocarbon HydroxylasesCell DeathEnzyme StabilityHEK293 CellsHep G2 CellsHumansModels, MolecularMutagenesis, InsertionalRabbitsRNA Splice SitesSerineTerpenes4-ipomeanolAryl Hydrocarbon Hydroxylasescytochrome P-450 CYP4B1RNA Splice SitesSerineTerpenes

Identifiers

PMID26355749
PMCPMC4565547
OpenAlexW2177257184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.